132 related articles for article (PubMed ID: 1448776)
1. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
[TBL] [Abstract][Full Text] [Related]
3. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
[TBL] [Abstract][Full Text] [Related]
4. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
5. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
6. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
8. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M.
Lee C; Barrowcliffe T; Bray G; Gomperts E; Hubbard A; Kemball-Cook G; Lilley P; Owens D; Von Tilberg L; Pasi J
Thromb Haemost; 1996 Dec; 76(6):950-6. PubMed ID: 8972016
[TBL] [Abstract][Full Text] [Related]
11. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
12. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
Smith KJ; Lusher JM; Cohen AR; Salzman P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
[TBL] [Abstract][Full Text] [Related]
13. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
White GC; Courter S; Bray GL; Lee M; Gomperts ED
Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
Mordenti J; Osaka G; Garcia K; Thomsen K; Licko V; Meng G
Toxicol Appl Pharmacol; 1996 Jan; 136(1):75-8. PubMed ID: 8560482
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
20. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.
Kessler CM; Gill JC; White GC; Shapiro A; Arkin S; Roth DA; Meng X; Lusher JM
Haemophilia; 2005 Mar; 11(2):84-91. PubMed ID: 15810908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]